A Phase 2 interventional study of Cholecalciferol in Hematologic Neoplasms, sponsored by Seoul National University Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-25.
Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment
Among 30 studies in Hematologic Neoplasms with a site in Korea, Republic of — 8 open to participants now, 11 under way, 3 of them phase 3. Hematologic Neoplasms · Korea, Republic of.
Among the 30 studies in Hematologic Neoplasms with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 2, and was the 16th registered.
1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →8 of the 30 studies in Hematologic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Sung-Han Kim · Sites in Korea, Republic of
Ages 19+
LucasBio · Sites in Korea, Republic of
Ages 19+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Kura Oncology, Inc. · Sites in Korea, Republic of, United States, Australia and 14 more countries
Ages 18+
Incyte Corporation · Sites in Korea, Republic of, Hungary, Italy and 2 more countries
Ages 18–99
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 81 across the 25 interventional studies, 108 across the 5 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 30 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 4 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Hematologic Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485855Phase 3Asan Medical CenterInfluenza Vaccination Strategy for Patients With Hematologic Malignancy | 2027-04-30 |
| NCT04634552Janssen Research & Development, LLCA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | 2027-06-30 |
| NCT07679412LucasBioEvaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis. | 2027-08-14 |
| NCT06465433Incyte CorporationExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | 2027-08-29 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Hematologic Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Graft-versus-host-disease (GVHD) is common complication of hematopoietic stem cell transplantation. Vitamin D deficiency has been shown to be associated with increased risk of chronic GVHD in previous clinical studies. The purpose of this research is to investigate the effect of vitamin D supplementation in patients undergoing hematopoietic stem cell transplantation
Hematopoietic stem cell transplant candidates are randomized to vitamin D supplementation or usual care. Five milligrams (200,000 IU) of cholecalciferol is injected to intervention group before stem cell transplantation. Additional supplementation of cholecalciferol during follow-up period is determined according to the level of 25(OH)D3. The primary outcome is the incidence of chronic GVHD which is determined according to IBMTR criteria. The secondary outcome consists of the incidence of acute GVHD, incidence and severity of vitamin D deficiency, and serum concentration of 25(OH)D3. Study investigators expect that supplementation of vitamin D may improve the outcome of stem cell transplantation by reducing the incidence of chronic GVHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cholecalciferol 5mg (200,000 IU)
Drug: Cholecalciferol
Usual care
Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
Also known as: Caldiferol
Chronic GVHD
Events will be graded according to IBMTR criteria
Time frame: Up to 1 year
Acute GVHD
Events will be graded according to IBMTR criteria
Time frame: Up to 100 days
Vitamin D deficiency
Severity and incidence of Vitamin D deficiency
Time frame: Up to 1 year
25(OH)D3
Serum concentration of 25(OH)D3
Time frame: Up to 1 year
Started Oct 2017 (actual). Primary completion is estimated for Dec 2018, 14 months after the start.
Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 14 months is below that.
Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cholecalciferol
Seoul National University Hospital →